AnaptysBio Inc

ANAB exhibits a bearish continuation of lower highs and lows, trading below declining EMAs and a modestly lower 200-day SMA. The medium-term bias is bearish, confirmed by volume-heavy down-days, while the short term favors selling into the current weakness around the recent low. Primary risk is a sharp oversold bounce or failure to break 200-day SMA support, which would stall the downtrend.

• ↑Proprietary platform advancing imsidolimab for GPP creates key pipeline catalyst.
• ↑3.72% yield offers income buffer amid biotech volatility.
• ↓Expected Q2 EPS of −$0.22 underscores persistent unprofitability.